Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

Core Viewpoint - Novartis is planning to acquire U.S.-based biotech Excellergy for up to $2 billion, focusing on a next-generation allergy treatment that may outperform current market options [1][2]. Group 1: Acquisition Details - The acquisition will incorporate Exl-111, an early-stage drug candidate, into Novartis' existing allergy portfolio, as part of a strategy to mitigate the impact of upcoming patent expirations [2]. - This deal follows Novartis' recent announcement of acquiring Synnovation subsidiary Pikavation Therapeutics for up to $3 billion to secure rights to an experimental breast cancer drug [2]. - The transaction is expected to close in the first half of 2026, pending regulatory approvals, with Novartis planning to make both upfront and milestone payments to Excellergy [3]. Group 2: Strategic Context - In February, Novartis completed the acquisition of Avidity Biosciences, adding three late-stage programs to its neuromuscular pipeline, with potential launches anticipated before 2030 [3]. - Excellergy's lead asset is still several years away from market availability, indicating a long-term investment strategy by Novartis [3]. Group 3: Market Reaction - Novartis stock showed little movement in morning trading in Zurich, reflecting a stable market response to the acquisition news [4].